Table 3. Assessment of risk of bias in studies.
| Study Site | Adequate sequence generation | Allocation assignment | Blinding of participants, personnel and outcome assessors | No evidence of incomplete outcome data | No evidence of selective outcome reporting | |
| Cisse (2006) [20] | Niakhar | Yes | Yes | Yes (double blind) | Yes | Yes |
| Kweku (2008) [22] | Hohoe | Yes | Yes | No (drug packers and principal investigator un-blinded) | Yes | Yes |
| Dicko (2008) [21] | Kambila | Yes | Yes | No (open label, control arm received no intervention) | Yes | Yes |
| Bojang (2010) [19] | Basse | No (control arm for malaria incidence/safety comparison non randomised) | Yes | No (open label) | No (higher loss to follow up in SP+AQ arm, 22% vs 11–12%, no obvious explanation) | Yes |
| Dicko (2011) [12] | Kati Region | Yes | Yes | Yes (double blind) | Yes | Yes |
| Konaté (2011) [13] | Boussé | Yes | Yes | Yes (double blind) | Yes | Yes |
| Sesay (2011) [23] | Farafenni | Not assessed (information not available) | ||||
| Sokhna (2008) [24] | Niakhar | No (villages chosen for logistical convenience, systematic allocation of individual children) | No (open label) | Yes | Yes | |
| Cisse (2009) [25] | Ndoffane | Yes | Yes | No (open label) | Yes | Yes |
| Bojang (2011) [26] | Basse | Yes | Yes | No (open label) | Yes | Yes |
| Kweku (2009) [27] | Jasikan | Yes | Yes | No (open label) | Yes | Yes |
| Cisse [28] (unpublished) | Tivaouane | Not assessed (information not available) | ||||
AQ: amodiaquine, SP: sulphadoxine pyrimethamine.